Data from a prospective cohort study emphasize the limitations of applying current WHO criteria of long COVID in patients with inflammatory rheumatic diseases.
Novavax s head of research and development said an updated vaccine the company is already producing is likely to be protective against other fast-growing coronavirus variants circulating in the US.
Compared with patients who were vaccinated and boosted, unvaccinated patients with COVID-19 had a 21-fold greater risk for hospitalization, data suggest.